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RAPAMYCIN PREVENTS GVHD IN MOUSE MODEL THROUGH NOVEL
MECHANISM: INCREASE IN REGULATORY T CELLS
Palmer, J.M., Chen, B.J., DeOliviera, D., Le, N., Chao, N.J. Duke
University, Durham, NC.
Rapamycin (RAPA) is an immunosuppressant that has been used
formany years for prevention of rejection in solid organ transplanta-
tion. It also appears to have some impact on acute graft versus host
disease (GVHD) after allogeneic hematopoietic stem cell transplan-
tation (HSCT). In previous experiments done in our lab, RAPA sig-
nificantly improves survival inGVHDmousemodel. Recently, it has
been found that RAPA can increase numbers or enhance survival of
regulatory T cells. In this experiment we further investigate the
mechanisms behind RAPA in amurineGVHDmodel. In several ex-
periments, B10.D2 bonemarrow and splenocytes were injected into
Balb/cmice.Themice had samples of peripheral blood and ear biop-
sies evaluated at two, four and six weeks post-transplantation. Regu-
latoryT cells were analyzed based on intracellular FoxP3 expression
via FACS or immunohistochemistry. At all three time points in the
peripheral blood, the percent of regulatory T cells in total CD41
cellswasnot significantlydifferent.Ondays14 and28 therewere sig-
nificant differences seen in the ear biopsies, both inmorphologic ap-
pearance and percent FoxP3 positive cells of mononuclear cells. On
day 14 there wasmore inflammation in the control arm compared to
the RAPA treatedmice, however, there was a cellular infiltrate pres-
ent in both. The percentage of FoxP3 positive cells was 13% in the
treated arm as compared to 2.5% in the control arm (p 5 0.02).
On day 28, there was a decrease in cellularity in the control arm as
compared to the RAPA arm, however in the RAPA arm there was
a significant increase in percent of FoxP3 positive cells as compared
to control arm: 9%vs 1.2% (p5 0.04).These results suggest that the
mechanism through which RAPA prevents GVHD in this model is
not only immunosuppression but also through the effects of regula-
tory T cells. It appears that the effect is mediated locally in the tis-
sues, rather than through circulating regulatory T cells.343
INITIAL THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE WITH
‘‘LOW-DOSE’’ PREDNISONE (1 mg/kg/day) INSTEAD OF ‘‘STANDARD-
DOSE’’ PREDNISONE (2 mg/kg/day) DOES NOT COMPROMISE MAJOR
OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION
Mielcarek, M., Storer, B., Martin, P.J. Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
The optimal glucocorticoid dose for initial treatment of acute
graft-versus-host disease (GVHD) remains to be defined. We hy-
pothesized that initial treatment with ‘‘low-dose’’ glucocortocoids
(equivalent to prednisone, 1 mg/kg/day) would not compromise
major transplantation outcomes compared to treatment with ‘‘stan-
dard-dose’’ glucocorticoids (equivalent to prednisone, 2 mg/kg/
day). In a retrospective review, we identified 347 patients with acute
GVHD who were treated initially with low-dose glucocorticoids
and 386 who were treated at standard doses. All patients were at
least 18 years of age and had transplants between 2000 and 2005
at a single institution. Fifty-eight (17%) of the 347 patients in the
low-dose group subsequently received standard-dose treatment af-
ter inadequate response to low-dose treatment. The mean cumula-
tive prednisone-equivalent doses across time in the low-dose group
were reduced by approximately 48% compared to the standard-dose
group. After adjusting for donor type (unrelated vs other), HLA-
mismatch (any vs other), patient age (continuous), conditioning
intensity (myeloablative vs nonmyeloablative), donor/recipient
gender disparity, prophylactic use of ursodeoxycholic acid and
tacrolimus, GVHD grade at onset of therapy and use of beclome-
thasone dipropionate (time-dependent covariate) in multivariate
analysis, we found no statistically significant differences in out-
comes in the low-dose group compared to the standard-dose group:
overall mortality (hazard ratio [HR], 0.99; 95% confidence interval
[CI], 0.8–1.3), relapse (HR, 1.14; 95% CI, 0.8–1.6), non-relapse
mortality (HR, 0.92; 95% CI, 0.7–1.3). Although the proportion
of patients receiving secondary therapy (including an increasefrom low dose to standard dose) was similar in the two groups,
the onset of secondary therapy occurred sooner in the low-dose
group (HR, 1.94; 95% CI, 1.3–2.8). Endpoints of prednisone-re-
lated morbidity were not assessed in this study. Results were similar
in subgroups of patients with GVHD characterized by rash involv-
ing#50%body surface area and stool volumes#1.0 Lwith or with-
out anorexia, nausea and vomiting (n5 425) and in those with more
severe GVHD (n 5 308). We conclude that, despite a nearly 50%
reduction in the cumulative glucocorticoid dose across time, initial
glucocorticoid treatment at a prednisone-equivalent dose of 1 mg/
kg/day was not associated with inferior outcomes when compared
to initial treatment with standard-dose glucocorticoids.344
OFF-THE-SHELF TUMOR IMMUNOTHERAPY WITH GENETICALLY EN-
HANCED ALLOGENEIC T-CELL PRECURSORS
Zakrzewski, J.L.1, Suh, D.1, Markley, J.C.2, Smith, O.M.1, King, C.1,
Goldberg, G.1, Jenq, R.1, Holland, A.M.1, Grubin, J.1, Cabrera-
Perez, J.1, Lu, S.X.1, Rizzuto, G.1, Sant’Angelo, D.B.1, Riviere, I.2,
Sadelain, M.2, Zuniga-Pflucker, J.C.3, van den Brink, M.R.M.1. 1 Me-
morial Sloan Kettering Cancer Center, New York, NY; 2 Memorial Sloan
Kettering Cancer Center, New York, NY; 3 University of Toronto, Tor-
onto, ON, Canada.
T cell deficiencies can occur in many physiological and patho-
physiological settings such as aging, malignant diseases, and cyto-
static therapy. We recently reported that co-transplantation of in
vitro generated T cell precursors significantly enhances T cell re-
constitution after allogeneicHSCT resulting in increased graft-ver-
sus-tumor activity without graft-versus-host disease. The aim of our
present study was to evaluate if allogeneic T cell precursors can
safely be transferred across MHC barriers in the absence of alloge-
neic HSCs to improve anti-tumor activity in immunosuppressed re-
cipients. We found that adoptively transferred allogeneic (C57BL/
6) precursor cells in irradiated hosts (BALB/c) develop into fully
functional allogeneic T cells characterized by a host-MHC re-
stricted and host-tolerant T cell receptor. We show that adoptively
transferred allogeneic T cell precursors significantly improve sur-
vival of BALB/c mice after irradiation (675 cGy) and enhance
anti-tumor activity against A20 lymphoma and renal cell carcinoma
in syngeneic HSCT recipients. Furthermore, we demonstrate the
feasibility of genetic engineering of antigen-specific T cell precur-
sors, by transducing them to express a chimeric antigen receptor
(CAR) targeting hCD19. Immunotherapy with CAR-expressing T
cell precursors resulted in the in vivo generation of high numbers
of appropriately selected T cells expressing the CAR, which
persisted for at least two months after transfer and mediated signif-
icantly enhanced anti-tumor activity (compared with CAR-negative
T cell precursors) against a CAR-sensitive tumor, without any un-
desirable auto/alloreactivity. We conclude that T cell precursors
from any donor can be used universally for adoptive immunother-
apy in any immunosuppressed individual irrespective of MHC dis-
parities. The use of allogeneic precursors cells instead of autologous
cells eliminates the risk of contamination with residual malignant
patient cells and allows the generation and storage of virtually un-
limited quantities of precursor cells for ‘off-the-shelf’ immunother-
apy. This procedure is not only labor and cost-effective, but it
facilitates the application of gene transfer technology, to generate
antigen-specific or otherwise enhanced designer cells. Adoptive
transfer of allogeneic and genetically enhanced T cell precursors
therefore represents a promising novel strategy for targeted ‘off-
the-shelf’ immunotherapy in immunosuppressed patients.345
DECREASED RISK OF ACUTE GVHD FOLLOWING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THE 5,10-
METHYLENETETRAHYDROFOLATE REDUCTASE 677TT GENOTYPE
Sugimoto, K.1, Murata, M.1, Onizuka, M.2, Inamoto, Y.2,
Terakura, S.1, Kuwatsuka, Y.2, Oba, T.2, Miyamura, K.2, Kodera, Y.2,
Naoe, T.1. 1 Nagoya University Graduate School of Medicine, Nagoya,
Aichi, Japan; 2 Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi,
Japan.
Poster Session II 1275,10-methylenetetrahydrofolate reductase (MTHFR) is a central
regulatory enzyme in folate metabolism. A common functional
polymorphism of the MTHFR gene occurs at C677T. The
677TT genotype produces an enzyme with only 30% of the activity
of the wild-type (677CC) enzyme. The MTHFR polymorphism has
been shown to affect the sensitivity of patients to folate-based drugs
such as methotrexate (MTX) that is used for GVHD prophylaxis
following allogeneic hematopoietic stem cell transplantation
(HSCT). To assess the significance of C677T genotypes in
HSCT using MTX as a GVHD prophylaxis, we analyzed DNA
from159 patients with a hematological disease and theirHLA-iden-
tical sibling donors using PCR-RFLP method. The frequencies of
CC, CT and TT genotypes in the patients were 35%, 52% and
13%, respectively, and in the donors were 30%, 62% and 8%, re-
spectively. There was no significant difference in the distribution
patterns of the C677T genotypes between patients and donors (P
5 0.19). Multivariate analysis revealed a significantly lower inci-
dence of grade I-IV acute GVHD in patients with the 677TT geno-
type (relative risk, 0.35; 95% confidence interval, 0.13–0.95; P 5
0.040) and a non-malignant disease (0.22; 0.05–0.89; 0.034). There
was a significant association between a lower incidence of grade II-
IV acute GVHD and the use of bone marrow for transplantation
(0.32; 0.11–0.91; 0.032). There was no association between the in-
cidence of acute GVHD and the donor C677T genotypes. We an-
alyzed the incidence of acute GVHD in relation to the MTHFR
genotype using the Kaplan-Meier method. The incidence of grade
I-IV acute GVHD in the patients with 677TT genotype was signif-
icantly lower than in those with 677CC/CT genotype (19% versus
45%, P 5 0.035). There was a trend for a lower incidence of grade
II-IV acute GVHD in patients with 677TT genotype compared
with 677CC/CT genotype (5% versus 24%, P 5 0.077). The
C677T genotypes in the patient or donor were not associated
with the treatment-related mortality, relapse rate, relapse-free sur-
vival and overall survival. These results suggest that greater immu-
nosuppression by MTX due to low MTHFR enzyme activity
decreases the risk of acute GVHD in recipients of allogeneic
HSCT. Further studies are needed to confirm that the MTHFR
C677T polymorphism can predict the outcome of HSCT using
prophylactic MTX to prevent GVHD.346
HOMEOSTATIC AND INFLAMMATORY PROCESSES CONTRIBUTE TO EL-
EVATED PLASMA LEVELS OF B CELL ACTIVATING FACTOR (BAFF) IN
CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
Hakim, F.T., Rehman, N., Dickinson, J., Beal, M., Baskar, S.,
Rader, C., Cowen, E., Pavletic, S., Gress, R.E. National Cancer Institute,
NIH, Bethesda, MD.
BAFF, a non-redundant cytokine produced by myeloid cells,
plays a critical role in the normal homeostatic maintenance, activa-
tion and function of B cells. Elevated circulating levels of BAFF,
however, have been observed in systemic autoimmune disorders
and, in murine models, have been linked to a failure to delete
auto-reactive B cells. We similarly observed elevated plasma
BAFF levels in 77 patients in an ongoingNCICGVHDnatural his-
tory protocol, with a median of 2845 pg/ml (range 92 to 17058), as
compared to 556 pg/ml (range 75 to 1834) in 18 normal donors.
Furthermore, in a subset of 22 patients in which severity of
CGVHD could be assessed by the presence of marked erythema
or sclerosis on 10 to 90% of their body surface areas (BSA), the
BAFF level correlated with the percentage of affected BSA (Spear-
man r51.63). We then explored the factors that might contribute
to elevated BAFF levels. In recipients recovering from either autol-
ogous or allogeneic transplant (without GVHD) we observed the
highest BAFF levels at day 0 (median of 10534 and 12240 pg/ml re-
spectively), when B cells were severely depleted. As B cell popula-
tions recovered to normal levels post transplant, plasma BAFF
concentrations declined (Spearman r 5 -.80 and r 5 -.60, respec-
tively), consistent with homeostatic cytokine-consumption dynam-
ics. Despite comparably high levels of BAFF (median of 11342 pg/
ml) at transplant day 0 in 16 patients who later developed CGHVD,
BAFF levels in the cross-sectional, natural history patient popula-
tion were only moderately correlated with the degree of post trans-
plant B cell recovery (r 5 -.48). Since inflammatory triggers caninduce elevated BAFF production by dendritic cells, we assessed
plasma levels of cytokines indicative of an inflammatory process.
In 34 patients, the plasma levels of IP-10 and sTNFRII correlated
positively with BAFF levels (r51.627 and r51.642, respectively),
consistent with active inflammatory processes in thoseCGVHDpa-
tients with elevated BAFF levels. In a multi-step regression model,
the levels of circulating B cells, plasma IP-10 and sTNFRII com-
bined to strongly predict BAFF levels (R 5 .834). These findings
suggest that both homeostatic recovery of B cell populations con-
suming BAFF and inflammatory cytokine cascades initiated by do-
nor-anti-host reactivity combine to regulate BAFF levels post
transplant.347
CORRELATION BETWEEN FOXP3 GENE POLYMORPHISMS IN DONORS,
AND THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PA-
TIENTS AFTER RELATED ALLOGENEIC STEM CELL TRANSPLANTATION
Perfecto-Avalos, Y.1, Borbolla Escoboza, J.R.1, Villela-Martiez, L.M.1,
Scott, S.P.1, Vela-Ojeda, J.2, Gonzalez-Ramella, O.3, Baltazar-
Arellano, S.4, Lopez-Hernandez, M.A.5. 1 ITESM Medical School, Mon-
terrey, Nuevo Leon, Mexico; 2 Centro Medico La Raza, IMSS, Mexico
City, DF, Mexico; 3 Hospital Civil de Guadalajara ‘‘Juan I Menchaca’’,
Guadalajara, Jalisco, Mexico; 4 HUMAE 25, IMSS, Monterrey, Nuevo
Leon, Mexico; 5 Centro Medico 20 de Noviembre, Mexico City, DF, Mex-
ico.
Introduction: Acute Graft-versus-host disease (aGVHD) is
a major complication of allogeneic stem cell transplantation (al-
loSCT). Risk factors include patient age, sex matching, CMV status
and degree of match. Regulatory T cells are critical for immune tol-
erance processes such as aGVHD, and express the transcription fac-
tor FOXP3, a member of the forkhead/winged-helix family,
identified as a key regulatory gene required for the development
and activity of these cells. It has been suggested that genetic expres-
sion of FOXP3 is inversely correlated with the severity of the
GVHD. We studied donors DNA looking for 5 polymorphisms
on the promoter region of the FOXP3 gene, and we tried to corre-
late them with presence and degree of aGVHD. Patients and
Methods: We studied donors of stem cells for allogeneic stem
cell transplants. We looked for the presence of the following poly-
morphisms by PCR: POL01–5906 T/A rs2869211; POL03–3279
A/C rs3761548; POL04–2383 C/T rs3761549; POL05–1383 C/T
rs2232364; POL06–924 A/G rs2232365.Results:Our sample con-
sisted of 31 donors, all siblings. In them we found only 2 of the 5
FOXP3 polymorphisms, either as homozygous or heterozygous.
These polymorphisms were found in 15/31 donors, with 12 being
homozygous (38.7%), and 3 heterozygous (9.7%). These genes
polymorphisms were POL03 y POL06. The most observed poly-
morphism was POL-06 with 9 cases, while POL-03 was found in
6 donors. Only sex difference and CMV status had an elevated haz-
ard ratio for developing GVHD (HR5 1.18, CI95%: 0.18 to 7.64;
p 5 0.85) and (HR 5 3.0, CI95%: 0.07 to 126; p 5 0.46) respec-
tively. We found no statistically significant difference in the inci-
dence of GVHD between patients who had received cells from
donor with or without a FOXP3 polymorphism (p 5 0.87). When
we analyzed the risk of presenting GVHD, results suggest that hav-
ing one of the 2 positive polymorphisms of the FOXP3 gene could
have a protective effect for the patient. For POL03 HR 5 0.87,
CI95%:0.18 to 4.14; p 5 0.86, and for POL06, HR 5 1, CI95%:
0.37 to 2.64, p5 0.67.Conclusions:Even though our sample is still
small to make conclusive remarks, we believe that our results point
toward some level of protection from acute GVHD in patients re-
ceiving cells from donors expressing POL03 and POL06. It is
also worthwhile mentioning the relatively high frequency of these
polymorphisms, as well as the absence of the other 3.348
HUMAN NEUTROPHIL ELASTASE STIMULATING CD41 AND CD81 T
CELLS IS A POTENTIAL PROTEIN VACCINE FOR LEUKEMIA PATIENTS
WITH DIVERSE HLA TYPES
Le, Q., Melenhorst, J.J., Hensel, N., Eniafe, R., Barrett, A.J. National
Heart, Lung and Blood Institute, NIH, Bethesda, MD.
